← SynDRA
MIRDAMETINIB
SynDRA canonical compound SYN0011671 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | MAP2K1 |
|---|
| Mechanism of action | Protein kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MEK inhibitor
- Protein kinase inhibitor
- MAP2K1 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- MAP2K2 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- PD-0325901
- Pd 03525901
- Pd 901
- PD 0325901
- PD-325901
- PD0325901
- PD325901
- S06-0029
- N-[((R)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
- N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide
- N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
- GOMEKLI
- PD-901
- DTXCID8024024
- CHEBI:88249
- RefChem:818905
- MEK Inhibitor PD0325901
- C16H14F3IN2O4
- Mirdametinib [USAN]
- Mirdametinib (USAN)
- NCGC00189075-01
- MFCD08435926
- UNII-86K0J5AK6M
- Ezmekly
- PD0325901(Mirdametinib)
- 4BM
- Ezmekly (TN)
- Gomekli (TN)
- Mirdametinib (GMP)
- MIRDAMETINIB [INN]
- MIRDAMETINIB [WHO-DD]
- SCHEMBL172904
- GTPL7935
- orb1300996
- PD0325901 (Mirdametinib)
- SCHEMBL29352748
- SCHEMBL29358470
- EX-A102
- BDBM104963
Look up MIRDAMETINIB in the interactive SynDRA portal →